These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 600960)

  • 1. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA
    Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The investigation and treatment of renal osteodystrophy.
    Catto GR; MacLeod M; Pelc B; Kodicek E
    Proc Eur Dial Transplant Assoc; 1975; 11():473-80. PubMed ID: 1197272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 4. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
    Silverberg DS; Bettcher KB; Dossetor JB; Overton TR; Holick MF; DeLuca HF
    Can Med Assoc J; 1975 Jan; 112(2):190, 193-5. PubMed ID: 1111876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R
    Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 13. Symptomatic renal osteodystrophy after renal transplantation: treatment with 1-alpha-hydroxycholecalciferol.
    Williams PS; Hillis AN; Carty AJ; Sells RA; Bone JM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2227-8. PubMed ID: 3274500
    [No Abstract]   [Full Text] [Related]  

  • 14. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S; Olgaard K
    Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
    Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
    Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
    Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A
    Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161
    [No Abstract]   [Full Text] [Related]  

  • 19. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.